ORBIT TECHNOLOGIES LTD.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2020

U.S. DOLLARS IN THOUSANDS

UNAUDITED

INDEX

	Page
Auditors' Letter	2
Consolidated Balance Sheets	3 - 4
Consolidated Statements of Income	5
Consolidated Statements of Comprehensive Income	6
Consolidated Statements of Changes in Equity	7 – 9
Consolidated Statements of Cash Flows	10 - 11
Note to Consolidated financial Statements	12

- - - - - - - - - -



Kost Forer Gabbay & Kasierer 144 Menachem Begin Road, Building A, Fax: +972-3-5622555 Tel-Aviv 6492102, Israel

Tel: +972-3-6232525

To: Orbit Technologies Ltd.

We have reviewed the financial information of Orbit Technologies Ltd. and its subsidiaries ("the Group"), which comprises the condensed consolidated balance sheet as of September 30, 2020 and 2019 and the related condensed consolidated statements of income, comprehensive income, changes in equity and cash flows for the nine and three months periods then ended in accordance with Review Standard 1 of the Institute of Certified Public Accountants in Israel.

Based on our review, in our review report dated November 19, 2020 we stated that nothing came to our attention that caused us to believe that the abovementioned interim financial information was not prepared, in all material respects, in accordance with IAS 34.

The accompanying financial information, which is derived from the abovementioned financial information, is condensed financial information and does not include disclosures required by IAS 34. If the omitted disclosures were included in the accompanying financial information, they might influence the user's conclusions about the consolidated financial position, results of operations and cash flows of the Company and subsidiaries. Accordingly, the accompanying financial information is not designed for those who are not informed about such matters.

Tel-Aviv, Israel November 19, 2020 KOST FORER GABBAY & KASIERER A Member of Ernst & Young Global

	Septem	ber 30,	December 31,
	2020	2019	2019
	Unau	dited	Audited
	U.S.	dollars in tho	usands
ASSETS			
CURRENT ASSETS:			
Cash and cash equivalents	12,518	12,004	12,263
Short-term deposits	5,208	18	5,148
Accounts receivable	11,208	10,198	12,187
Other accounts receivable	885	720	646
Inventories	6,876	8,545	7,340
Amounts due for construction contracts	5,193	4,921	3,560
	41,888	36,406	41,144
NON-CURRENT ASSETS:			
Long-term other assets	10	192	10
Fixed assets	8,023	5,283	8,895
Intangible assets	5,619	5,796	5,750
Deferred taxes	683	632	575
	14,335	11,903	15,230
	56,223	48,309	56,374

	September 30,		December 31,
	2020	2019	2019
	Unaud	lited	Audited
	U.S.	dollars in thou	ısands
LIABILITIES AND EQUITY			
CURRENT LIABILITIES:			
Current maturities of Convertible Bonds	_	2,446	2,456
Trade payables	5,421	7,413	5,672
Income taxes payable	49	6	72
Other accounts payable	11,782	10,770	11,187
	17,252	20,635	19,387
NON-CURRENT LIABILITIES:			
Liability for Government grants	716	838	873
Employee benefit liability	266	579	259
Lease payments liability	3,838	583	4,585
Warranty	341	339	329
Deferred taxes	13	17	14
	5,174	2,356	6,060
EQUITY:			
Share capital	6,455	5,758	6,450
Paid-in capital	20,772	15,906	20,725
Warrants	1,761	1,904	1,761
Retained earnings	4,641	1,765	1,808
Reserve for share-based payment	805	989	763
Proceeds from conversion option	-	10	10
Foreign currency translation adjustments	(463)	(563)	(416)
Reserve for defined benefit plans	693	416	693
Treasury shares	(867)	(867)	(867)
Total equity	33,797	25,318	30,927
	56,223	48,309	56,374

November 19, 2020			
Date of approval of the	Yitzchak Gat	Daniel Eshchar	Meirav Dudek
financial statements	Chairman of the Board	CEO	CEO Deputy & CFO

CONSOLIDATED STATEMENTS OF INCOME

	Nine months ended September 30,		Three mor	Year ended December 31,	
	2020	2019	2020	2019	2019
		Unau	dited		Audited
	U.S. d	cept per sh	nare data)		
Revenues from sales and contracts	26.250	20.445	10.505	12.206	-1 CO
performed	36,379	38,447	12,725	13,306	51,762
Cost of sales and contracts performed	24,706	26,379	7,888	9,271	35,953
Gross profit	11,673	12,068	4,837	4,035	15,809
Research and development costs, net	2,358	2,722	1,000	782	3,525
Selling and marketing expenses	3,209	3,653	1,170	1,176	4,739
General and administrative expenses	2,662	2,888	843	801	3,898
1			-		
Operating income before other expenses	3,444	2,805	1,824	1,276	3,647
Other expenses	100	-,005	54	-	516
other expenses					310
Operating income after other expenses	3,344	2,805	1,770	1,276	3,131
Finance income	208	379	42	143	164
Finance expenses	631	947	385	267	891
1					
Profit before taxes on income	2,921	2,237	1,427	1,152	2,404
Tax expenses	88	44	38	12	168
•					
Net profit	2,833	2,193	1,389	1,140	2,236
Net profit per share attributable to equity holders of the Company (in U.S. dollars):					
Basic profit per share	0.153	0.136	0.075	0.071	0.136
Diluted profit per share	0.153	0.123	0.075	0.066	0.123
1 1					

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

	Nine months ended September 30,		Three mon Septem	Year ended December 31,	
	2020	2019	2020	2019	2019
		Unau	ıdited		Audited
		U.S.	dollars in th	ousands	
Net profit	2,833	2,193	1,389	1,140	2,236
Other comprehensive income (net of tax effect):					
Actuarial profit (loss) from defined benefit plans Foreign currency translation adjustments	-	(63)	(14)	(38)	214
of foreign operation	(47)	(92)	82	(70)	55
Total other comprehensive income (loss)	(47)	(155)	68	(108)	269
Total comprehensive income	2,786	2,038	1,457	1,032	2,505

	Equity attributable to equity holders of the Company												
						Foreign							
	G.	B		D () 1	Reserve for	currency	Proceeds from	Reserve for	T	T			
	Share capital	Paid-in capital	Warrants	Retained earnings	share-based payment	translation adjustments	conversion option	defined benefit plans	Treasury shares	Total equity			
					I - J	Unaudited		,					
	U.S. dollars in thousands												
Balance at January 1, 2020 (audited)	6,450	20,725	1,761	1,808	763	(416)	10	693	(867)	30,927			
Net profit	-	-	-	2,833	-	-	-	-	-	2,833			
Other comprehensive income (loss)						(47)	-			(47)			
Total comprehensive loss (loss)	-	_	-	2,833	-	(47)	-	-	_	2,786			
Exercise of warrants into shares	5	27	-	-	(4)	-	-	-	-	28			
Forfeiture of Options	-	20	-	-	(10)	-	(10)	-	-	-			
Cost of share based-payment			-	<u>-</u>	56	-	<u> </u>			56			
Balance at September 30, 2020	6,455	20,772	1,761	4,641	805	(463)		693	(867)	33,797			

	Equity attributable to equity holders of the Company											
	Share capital	Paid-in capital	Warrants	Retained earnings	Reserve for share-based payment	Foreign currency translation adjustments	Proceeds from conversion option	Reserve for defined benefit plans	Treasury shares	Total equity		
					TI C	Unaudited						
	U.S. dollars in thousands											
Balance at January 1, 2019 (audited) Net profit Other comprehensive income (loss)	5,758	15,890	1,904	(428) 2,193	997 - 	(471) - (92)	20	479 - (63)	(867)	23,282 2,193 (155)		
Total comprehensive loss (loss) Exercise of warrants into shares Forfeiture of Options Cost of share based-payment	- *)- - -	2 14	- - - -	2,193	(2) (4) (2)	(92)	(10)	(63) - - -	- - - -	2,038		
Balance at September 30, 2019	5,758	15,906	1,904	1,765	989	(563)	10	416	(867)	25,318		

	Equity attributable to equity holders of the Company												
	Share capital	Paid-in capital	Warrants	Retained earnings	Reserve for share-based payment	Foreign currency translation adjustments	Proceeds from conversion option	Reserve for defined benefit plans	Treasury shares	Total equity			
					II C d	Unaudited lollars in thousan	da						
					U.S. 0	ionars in thousan	us						
Balance at July 1, 2020	6,452	20,752	1,761	3,252	792	(545)	-	707	(867)	32,304			
Net profit	-	-	-	1,389	-	=	-	-	=	1,389			
Other comprehensive income (loss)						82		(14)		68			
Total comprehensive loss (loss)	-	-	-	1,389	-	82	-	(14)	-	1,457			
Exercise of options into shares	3	17	-	-	(3)	-	-	-	-	17			
Forfeiture of Options	-	3	-	-	(3)	-	-	-	-	-			
Cost of share based-payment		-	-	-	19		-	· 		19			
Balance at September 30, 2020	6,455	20,772	1,761	4,641	805	(463)		693	(867)	33,797			

	Equity attributable to equity holders of the Company											
	Share capital	Paid-in capital	Warrants	Retained earnings	Reserve for share-based payment	Foreign currency translation adjustments	Proceeds from conversion option	Reserve for defined benefit plans	Treasury shares	Total equity		
					***	Unaudited						
	U.S. dollars in thousands											
Balance at July 1, 2019 Net profit	5,758	15,902	1,904	625 1,140	974	(493)	10	454	(867)	24,267 1,140		
Other comprehensive income (loss)				<u> </u>		(70)	=	(38)		(108)		
Total comprehensive loss (loss)	-	<u>-</u>	-	1,140	-	(70)	-	(38)	-	1,032		
Forfeiture of Options Cost of share based-payment	<u> </u>	4 		-	(4) 19	-		- -		19		
Balance at September 30, 2019	5,758	15,906	1,904	1,765	989	(563)	10	416	(867)	25,318		

^{*)} Less than 1 thousands.

	Equity attributable to equity holders of the Company											
	Share capital	Paid-in capital	Warrants	Retained earnings	Reserve for share- based payment	Foreign currency translation adjustment s	Proceeds from conversion option	Reserve for hedges	Reserve for defined benefit plans	Treasury shares	Total equity	
	U.S. dollars in thousands											
Balance at January 1, 2019	5,758	15,890	1,904	(428)	997	(471)	20	-	479	(867)	23,282	
Net Income Other comprehensive income (loss)		-	- -	2,236	<u>-</u>	55	<u>-</u>		214	<u>-</u>	2,236 269	
Total comprehensive loss (loss) Exercise of warrants into shares by	-	-	-	2,236	-	55	-	-	214	-	2,505	
controlling shareholder	687	4,576	(143)	-	-	-	-	-	-	-	5,120	
Exercise of options into shares	5	57	_	-	(57)	-	-	-	-	-	5	
Forfeiture of options	-	202	-	-	(192)	-	(10)	-	-	-	-	
Cost of share based-payment			-		15						15	
Balance at December 31, 2019	6,450	20,725	1,761	1,808	763	(416)	10		693	(867)	30,927	

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine months ended T September 30,		Three mon Septeml		Year ended December 31,
	2020	2019	2020	2019	2019
		Unau	ıdited		Audited
		U.S	. dollars in tl	nousands	
Cash flows from operating activities:					
Net income	2,833	2,193	1,389	1,140	2,236
Adjustments to reconcile loss to net cash provided by operating activities:					
Adjustments to the profit or loss items:					
Depreciation and amortization	1,921	2,007	623	693	2,704
Capital gain from sale of fixed assets	-	_	-	-	338
Cost of share-based payment	56	(2)	19	19	15
Tax expense	88	44	38	12	168
Interest expenses, net	160	204	56	(57)	296
Change in employee benefit liability, net	7	53	6	20	10
Adjustment to current accounts with	,		· ·		10
foreign operation	122	40	90	82	31
	2,354	2,346	832	769	3,562
Changes in operating asset and liability items:	2,334	2,540	032	707	3,302
Decrease (increase) in trade receivables Decrease (increase) in amounts due for	979	383	(1,054)	(1,501)	(1,606)
construction contracts	(1,633)	(507)	482	884	855
Decrease (increase) in other accounts	(220)	(1.40)	(200)	((67)
receivable	(239)	(140)	(200)	6	(67)
Decrease (increase) in inventories	464	(1,052)	16	(245)	154
Increase (decrease) in trade payables	(338)	1,842	257	587	66
Increase (decrease) in other accounts payable	426	(261)	525	(460)	539
Cash paid and received during the period	(341)	265	26	(729)	(59)
for:					
Interest paid	(286)	(242)	(64)	(15)	(359)
Interest received	143	129	21	39	164
Taxes paid	(53)	(58)	(10)	(41)	(107)
	(196)	(171)	(53)	(17)	(302)
Net cash provided by operating activities	4,650	4,633	2,194	1,163	5,437

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine months ended September 30,		Three months ended September 30,		Year ended December 31,
	2020	2019	2020	2019	2019
	Unaudited			Audited	
		U.S. dollars in thousands			
Cash flows from investing activities:					
Purchase of fixed assets Capitalization of research and development	(430)	(748)	(153)	(252)	(1,097)
costs Restricted cash in respect of right to use	(345)	(443)	(96)	(96)	(555)
asset	-	-	-	-	182
Deposit in banking corporations	(60)	-	(10)	-	(5,130)
Proceeds from sale of fixed assets					4
Net cash used in investing activities	(835)	(1,191)	(259)	(348)	(6,596)
Cash flows from financing activities:					
Receipt of Government grants	4	81	-	-	84
Payments for Government grants	(42)	(19)	(39)	(11)	(19)
Payments of convertible bonds	(2,462)	(2,462)	-	-	(2,462)
Exercise of warrants into shares by					
controlling shareholder	- (0.64)	- (0.60)	-	- (22.5)	5,120
Payments of lease liability	(964)	(968)	(312)	(325)	(1,292)
Exercise of warrants into shares	28	2	17	2	5
Net cash provided by (used in) financing					
activities	(3,436)	(3,366)	(334)	(334)	1,436
Translation differences on balances of cash					
and cash equivalents	(124)	(85)	(91)	(46)	(27)
In annual (dannara) in each and each					
Increase (decrease) in cash and cash equivalents	255	(9)	1,510	435	250
Cash and cash equivalents at the beginning	233	())	1,510	733	230
of the period	12,263	12,013	11,008	11,569	12,013
·					
Cash and cash equivalents at the end of the					
period	12,518	12,004	12,518	12,004	12,263
Significant non-cash transaction:					
Purchase of fixed assets on suppliers credit	117	56	117	56	97
Recognition of the right of use against a lease liability	69	1,239		1,239	5,371
· ;			:		

NOTE 1:- GENERAL

These financial statements have been prepared in a condensed format as of September 30, 2020 and for the nine and three months then ended ("interim financial statements"). These financial statements should be read in conjunction with the Company's annual financial statements as of December 31, 2019 and for the year then ended and accompanying notes ("annual financial statements").
